Where is Cell2in located?

Cell2in is headquartered in Seoul, South Korea.

Is Cell2in a funded company?

Cell2in is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Cell2in rank among its competitors?

Cell2in ranks 127th amongst 190 active competitors, of which 34 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was RareCyte, which secured $658K in May, 2025.

Who are the top competitors of Cell2in?

Cell2in's top competitors include Qiagen, Parse Biosciences and RareCyte. Among them, RareCyte secured the most recent funding round in May, 2025.

Cell2in - 2026 Company Profile, Team, Funding & Competitors

Company Details

Cell2in develops probes and oligos for molecular biology research. They have developed their product FreSHtracer, a fluorescent dye that measures the level of Glutathione(GSH) in living cells. It is a small molecular probe that penetrates into cells and all cellular components. They offer services including cell therapy, quality control of stem cells, cell culture media, antioxidant screening, and others.

Website: cell2in.com
Email ID: *****@cell2in.com

Key Metrics

Founded Year

2016

Location

Seoul, South Korea

Stage

Funding Raised

Investors

Honest Ventures

Ranked

127^th among 190 active competitors

Similar Companies

Qiagen & 256 more

View Cell2in's full profile

Cell2in is a funded company. Cell2in has 1 institutional investor.

View details of Cell2in's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cell2in include Qiagen, Parse Biosciences and RareCyte. Here is the list of Top 10 competitors of Cell2in, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Qiagen 1984, Venlo (Netherlands), Acquired	Provider of products and reagents for molecular diagnostic assays	-	Life Sciences Partners, Harmonic & 6 others	65/100
2nd	Parse Biosciences 2018, Seattle (United States), Series C	Developer of RNA-sequencing solution-based transcriptome kit to analyze health data	$100M	Janus Henderson Investors, Marshall Wace & 8 others	64/100
3rd	RareCyte 2009, Seattle (United States), Series C	Developer of technologies for the analysis of rare and single cells in the blood	$114M	Arboretum Ventures, F-Prime Capital & 11 others	57/100
4th	Neogen 1982, Lansing (United States), Acquired	Solutions for food and animal safety, diagnostics, and genomics	$700K	Innovative Ventures, NISA	57/100
5th	Sebia 1967, Evry Courcouronnes (France), Acquired	Developer of electrophoresis-based in vitro diagnostics products	-	HarbourVest Partners, Astorg Partners & 4 others	56/100
6th	Genomtec 2016, Wroclaw (Poland), Series A	Provider of handheld POC device for nucleic acid testing	$4.38M	KnowledgeHub, EIC Fund & 5 others	55/100
7th	Nanosphere 1999, Northbrook (United States), Acquired	Provider of diagnostic tests for personalized medicine	$97.8M	Ann Lurie, Bain Capital Ventures & 8 others	52/100
8th	NuProbe 2016, George Town (Cayman Islands), Series B	Develops sensitive multiplex tool for QPCR	$61M	Sequoia Capital, Yonghua Capital & 14 others	51/100
9th	Novacyt 2005, Velizy Villacoublay (France), Public	A molecular diagnostics company specializing in genomic medicine solutions	-	Eiffel Investment Group, Kreos Capital & 2 others	50/100
10th	Fluent BioSciences 2018, Watertown (United States), Acquired	Developer of reagent for DNA analysis for genetic analysis	$19M	Samsara BioCapital, Illumina Ventures & 6 others	49/100
127th	Cell2in 2016, Seoul (South Korea), Funding Raised	Developer of probes and oligos for molecular biology research	-	Honest Ventures	24/100